BY ALLERGIC LIVING When the U.S. Food and Drug Administration (FDA) approved a new oral immunotherapy (OIT) for peanut allergy… Read more »
The Food and Drug Administration on Jan. 31 approved Palforzia, Aimmune Therapeutics’ oral immunotherapy (OIT) treatment for peanut allergy in… Read more »
A systematic review of peanut oral immunotherapy that compared 12 controlled studies has brought a longstanding “pro or con” debate… Read more »
Thoughts on where food allergy innovation and awareness need to head – to truly transform the lives of parents.
Study had at-risk children avoid peanuts for 12 months.
A new pilot study has resulted in subjects being able to tolerate 160 to 400 times more peanut than they could at the study’s outset.
State of food allergy research in 2013, and the obstacles to overcome.
“This is a massive research project which will have far reaching consequences for consumers and food producers,” said professor Clare Mills of the University of Manchester